All In Biotech

Drug Trial Radar · NCT00309985

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 790 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

790

Actual

Start

Sep 26, 2006

Primary completion

Dec 23, 2013

Study completion Jan 31, 2025

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Apr 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer

Interventions

  • androgen-deprivation therapyDrug

    LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.

  • docetaxelDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry

Locations

343 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Cancer Center

    Anchorage, Alaska

  • Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center

    Fort Smith, Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Alta Bates Summit Comprehensive Cancer Center

    Berkeley, California

  • Peninsula Medical Center

    Burlingame, California

  • California Cancer Care, Incorporated - Greenbrae

    Greenbrae, California

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Tibotec Therapeutics - Division of Ortho Biotech Products, LP

    Marysville, California

  • Mather Veteran Affairs Medical Center

    Mather, California

  • Mercy Cancer Center at Mercy Medical Center

    Merced, California

  • Memorial Medical Center

    Modesto, California

  • Sutter Health - Western Division Cancer Research Group

    Novato, California

  • University of California Davis Cancer Center

    Sacramento, California

  • California Pacific Medical Center - California Campus

    San Francisco, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Saint Helena Hospital

    St. Helena, California

  • Tahoe Forest Cancer Center

    Truckee, California

  • Sutter Solano Medical Center

    Vallejo, California

  • University of Colorado Cancer Center at UC Health Sciences Center

    Aurora, Colorado

  • Veterans Affairs Medical Center - Denver

    Denver, Colorado

  • Shaw Regional Cancer Center

    Edwards, Colorado

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Front Range Cancer Specialists

    Fort Collins, Colorado

  • St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

    Grand Junction, Colorado

  • Montrose Memorial Hospital Cancer Center

    Montrose, Colorado

  • Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

    Hartford, Connecticut

  • Yale Cancer Center

    New Haven, Connecticut

  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

    Washington D.C., District of Columbia

  • George Washington University Medical Center

    Washington D.C., District of Columbia

  • Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital

    Fort Lauderdale, Florida

  • University of Florida Shands Cancer Center

    Gainesville, Florida

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Ella Milbank Foshay Cancer Center at Jupiter Medical Center

    Jupiter, Florida

  • CCOP - Mount Sinai Medical Center

    Miami Beach, Florida

  • Northeast Georgia Medical Center

    Gainesville, Georgia

  • Mountain States Tumor Institute at St. Luke's Regional Medical Center

    Boise, Idaho

  • Saint Luke's Mountain States Tumor Institute - Fruitland

    Fruitland, Idaho

Showing 40 of 343 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.